Last 17 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 105.48 | — | 35.00 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.31 | 2.28 | 2.24 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 8.97 | 12.84 | 9.36 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 172.19 | 80.46 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 54.82 | 53.20 | 19.53 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 58.62 | — | 16.53 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Telix Pharmaceuticals Limited's operating margin was 2.7% in Q2 2025, down 8.8 pp QoQ and down 11.6 pp YoY. The trailing four-quarter average of 7.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 18.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.1% | 48.6% | 64.9% | 65.6% | 79.5% | 41.1% | 33.0% | -64.8% | -402.4% | -384.1% | -228.9% | -536.7% | -342.1% |
| — | +18.2% | +96.8% | +201.2% | +119.8% | +110.7% | +114.4% | +87.9% | -17.6% | -13.1% | -1.3% | — | -442.1% | |
| Operating Margin | 10.5% | 2.7% | 11.5% | 7.3% | 7.1% | 14.2% | -7.1% | -264.0% | -1065.2% | -1085.9% | -808.2% | -1251.3% | -1443.5% |
| — | -81.3% | +261.3% | +102.8% | +100.7% | +101.3% | +99.1% | +78.9% | +26.2% | -21.9% | +90.8% | — | +85.8% | |
| Net Margin | 6.4% | -0.6% | 6.4% | 6.2% | 6.9% | -6.5% | -24.4% | -294.8% | -1024.2% | -1117.3% | -737.3% | -1138.8% | -1049.3% |
| — | +90.9% | +126.4% | +102.1% | +100.7% | +99.4% | +96.7% | +74.1% | +2.4% | -95.8% | +83.4% | — | +89.3% |
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.9% | -0.7% | 7.9% | 4.2% | 17.4% | -18.4% | -35.8% | -131.8% | -191.6% | -51.2% | -40.1% | -29.6% | -30.9% |
| — | +96.2% | +122.0% | +103.2% | +109.1% | +64.2% | +10.6% | -345.8% | -520.4% | -137.4% | -125.5% | -166.8% | -79.2% | |
| ROA | 5.2% | -0.3% | 3.4% | 2.0% | 5.5% | -5.0% | -13.9% | -43.5% | -40.2% | -22.2% | -20.2% | -18.2% | -20.8% |
| — | +94.9% | +124.3% | +104.7% | +113.7% | +77.4% | +31.0% | -139.8% | -93.2% | -52.0% | -46.3% | -74.2% | -25.7% | |
| ROIC | 25.5% | 2.2% | 13.7% | 5.9% | 5475.0% | — | — | — | — | -1441.2% | -122.5% | -50.2% | -57.8% |
| — | — | — | — | — | — | — | — | — | -3682.6% | -124.4% | +38.3% | +88.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Telix Pharmaceuticals Limited's Debt/EBITDA ratio is 15.8x, up from 8.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 13.3% YoY to 1.33x, tightening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.02 | 0.99 | 1.02 | 0.05 | 0.12 | 0.17 | 0.13 | 0.02 | 1.18 | 0.04 | 0.03 | 0.06 | 0.03 |
| — | +475.4% | +683.7% | +125.2% | -90.0% | +386.9% | +367.5% | -57.5% | +3769.2% | -15.3% | -14.5% | +596.8% | +333.9% | |
| Debt / EBITDA | 6.62 | 15.81 | 8.76 | 1.27 | 0.79 | 0.38 | — | — | — | — | — | — | — |
| — | +4089.8% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.78 | 1.33 | 2.78 | 0.99 | 1.43 | 1.54 | 2.02 | 3.21 | 1.25 | 3.15 | 4.69 | 4.32 | 5.52 |
| — | -13.3% | +37.1% | -69.2% | +14.1% | -51.3% | -56.8% | -25.7% | -77.3% | -21.2% | +7.8% | -65.2% | -83.6% | |
| Quick Ratio | 2.66 | 1.22 | 2.66 | 0.87 | 1.32 | 1.45 | 1.93 | 3.07 | 1.16 | 3.11 | 4.66 | 4.28 | 5.47 |
| — | -16.2% | +38.2% | -71.7% | +13.6% | -53.5% | -58.7% | -28.2% | -78.8% | -19.3% | +9.1% | -65.6% | -83.8% | |
| Interest Coverage | 3.83 | 4.03 | 4.14 | 2.78 | 36.63 | 71.13 | -36.21 | -460.10 | -479.96 | -371.76 | -31.00 | -85.57 | -17.92 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 17 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying TLX stock.
Telix Pharmaceuticals Limited's current P/E is 105.5x. The average P/E over the last 1 quarters is 35.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Telix Pharmaceuticals Limited's current operating margin is 10.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Telix Pharmaceuticals Limited's business trajectory between earnings reports.